Susceptibility of Urinary Tract Bacteria to Fosfomycin

ABSTRACT We evaluated the in vitro activity of fosfomycin against urinary isolates in a region in Greece that exhibits considerable antimicrobial resistance by evaluating retrospectively relevant susceptibility data retrieved from the microbiological library of the University Hospital of Heraklion, Crete, Greece. We examined 578 urinary isolates. In total, 516 (89.2%) were susceptible to fosfomycin; 415 isolates were gram negative, and 101 isolates were gram positive. Fosfomycin appears to exhibit good levels of in vitro activity against the examined urinary isolates.

[1]  E. Baron,et al.  Specimen Collection, Transport, and Processing: Bacteriology , 2011 .

[2]  M. Falagas,et al.  Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. , 2009, International journal of antimicrobial agents.

[3]  M. Falagas,et al.  Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies , 2009, Expert opinion on investigational drugs.

[4]  M. Jl,et al.  [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin]. , 2009 .

[5]  P. Nordmann,et al.  Addressing the challenge of extended-spectrum beta-lactamases. , 2009, Current opinion in investigational drugs.

[6]  J. Andrews.  BSAC standardized disc susceptibility testing method (version 8). , 2004, The Journal of antimicrobial chemotherapy.

[7]  J. Rodríguez,et al.  Actividad in vitro de fosfomicina frente a enterobacterias de origen urinario productoras de betalactamasas de espectro extendido , 2009 .

[8]  J. Munoz,et al.  [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin]. , 2009, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[9]  G. Miragliotta,et al.  Antimicrobial Resistance among Uropathogens Responsible for Community-Acquired Urinary Tract Infections in an Italian Community , 2008, Journal of chemotherapy.

[10]  D. Talan,et al.  Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  M. Falagas,et al.  Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials. , 2008, Current medical research and opinion.

[12]  T. Mackenzie,et al.  Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. , 2008, The American journal of medicine.

[13]  M. Falagas,et al.  Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials. , 2008, Clinical therapeutics.

[14]  A. Oliver,et al.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. , 2008, Archives of internal medicine.

[15]  S. Sforza,et al.  Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli. , 2008, The Journal of infection.

[16]  L. Bernard,et al.  Prescription de la fosfomycine en situation critique , 2008 .

[17]  A. Marchese,et al.  European Emergence of Ciprofloxacin-Resistant Escherichia coli Clonal Groups O25:H4-ST 131 and O15:K52:H1 Causing Community-Acquired Uncomplicated Cystitis , 2008, Journal of Clinical Microbiology.

[18]  B. Lobel,et al.  Comparaison de la sensibilité aux antibiotiques de 1 217 isolats consécutifs de Escherichia coli responsables d’infections urinaires féminines en ville et à l’hôpital , 2008 .

[19]  M. Falagas,et al.  Fosfomycin: use beyond urinary tract and gastrointestinal infections. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  N. Mandras,et al.  Role of Fosfomycin Tromethamine in Modulating Non-Specific Defence Mechanisms in Chronic Uremic Patients towards ESBL-Producing Escherichia Coli , 2008, International journal of immunopathology and pharmacology.

[21]  L. Bernard,et al.  [Fosfomycin prescription during production shortage]. , 2008, Medecine et maladies infectieuses.

[22]  P. Wayne.  PERFORMANCE STANDARDS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING, NINTH INFORMATIONAL SUPPLEMENT , 2008 .

[23]  O. Gaillot,et al.  [Comparison of antimicrobial susceptibility of 1,217 Escherichia coli isolates from women with hospital and community-acquired urinary tract infections]. , 2008, Presse medicale.

[24]  Treatment of Urinary Tract Infections in Nonpregnant Women , 2008 .

[25]  M. Falagas,et al.  Citrobacter infections in a general hospital: characteristics and outcomes , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[26]  M. Falagas,et al.  Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[27]  P. Ho,et al.  Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes. , 2007, Diagnostic microbiology and infectious disease.

[28]  J. Sifuentes-Osornio,et al.  [Microbiology of urinary tract infections in ambulatory patients. Therapeutic options in times of high antibiotic resistance]. , 2007, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[29]  K. Bush,et al.  Carbapenemases: the Versatile β-Lactamases , 2007, Clinical Microbiology Reviews.

[30]  R. Dal-Ré,et al.  Quinolone resistance in female outpatient urinary tract isolates of Escherichia coli: age-related differences. , 2007, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[31]  R. Saavedra,et al.  Resistencia a las quinolonas en aislamientos de Escherichia coli procedentes de mujeres con cistitis aguda extrahospitalaria: diferencias en relación con la edad , 2007 .

[32]  G. Mazzaglia,et al.  Antibiotic prescribing for acute and recurrent cystitis in primary care: a 4 year descriptive study. , 2006, The Journal of antimicrobial chemotherapy.

[33]  Á. Pascual,et al.  In Vitro Activity of Fosfomycin against Extended-Spectrum-β-Lactamase- Producing Escherichia coli and Klebsiella pneumoniae: Comparison of Susceptibility Testing Procedures , 2006, Antimicrobial Agents and Chemotherapy.

[34]  T. Griebling.  Urologic diseases in america project: trends in resource use for urinary tract infections in men. , 2005, The Journal of urology.

[35]  B. Pangon,et al.  Pyélonéphrite aiguë : bactériologie et évolution des résistances ☆ , 2003 .

[36]  G. Schito.  Why fosfomycin trometamol as first line therapy for uncomplicated UTI? , 2003, International journal of antimicrobial agents.

[37]  B. Foxman,et al.  Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. , 2003, Annals of epidemiology.

[38]  B. Pangon,et al.  [Acute pyelonephritis: bacteriological data and general course of germ resistance]. , 2003, Pathologie-biologie.

[39]  Betsy Foxman,et al.  Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. , 2002, The American journal of medicine.

[40]  W. Stamm,et al.  Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. , 2002, International journal of antimicrobial agents.

[41]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[42]  J. Andrews.  BSAC standardized disc susceptibility testing method. , 2001, The Journal of antimicrobial chemotherapy.

[43]  A. Schaeffer,et al.  Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  G. Stein.  Single-Dose Treatment of Acute Cystitis with Fosfomycin Tromethamine , 1998, The Annals of pharmacotherapy.

[45]  J. Balfour,et al.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. , 1997, Drugs.

[46]  F. Goldstein,et al.  Communiqué 1992 du comité de l'antibiogramme de la société française de microbiologie , 1990 .

[47]  W. Stamm,et al.  Urinary tract infections in women: diagnosis and treatment. , 1989, Annals of internal medicine.

[48]  W. Jędrzejczyk,et al.  [Abdominal approach in the surgical treatment of hiatal hernia]. , 1976, Polski przeglad chirurgiczny.

[49]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .